Home | Welcome to Contract Pharma   
Last Updated Saturday, November 1 2014
Print

Financial Report: BASi



Published October 18, 2013
BASi
 
3Q Revenues:
$5.6 million (-22%)

3Q Earnings: $576,000 (loss of $246,000 3Q12)

YTD Revenues: $16.6 million (-24%)

YTD Earnings: $521,000 (loss of $3.6 million YTD13)

Comments: Service revenue for the quarter was down 20% to $4.2 million, impacted by the consolidation of BASi's Oregon lab into its West Lafayette facility. Product revenue decreased 27% to $1.4 million, primarily due to lower sales of Culex automated sampling systems. Earnings in the quarter are attributed to a higher gross margin and lower operating expenses. Restructuring charges impacted 2012 earnings.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On